At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 160 enrolled
Drug / intervention
aldafermin +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluation of Efficacy, Safety and Tolerability of NGM282 (Aldafermin) in a Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (ALPINE 4)
In Brief
A Phase 2 clinical trial evaluating aldafermin and Placebo for Compensated Cirrhosis and Nonalcoholic Steatohepatitis. Completed, enrolled 160 participants across 49 sites in 9 countries.
Detailed Summary
A multi-center evaluation of aldafermin in a randomized, double-blind, placebo-controlled study in subjects with compensated cirrhosis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesAustralia, Belgium, France, Germany, Hong Kong, Poland, Puerto Rico, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedDec 2019
Enrollment StartMar 2020
Primary CompletionJan 2023
Study CompletionFeb 2023
TodayJul 2026
First PostedDec 24, 2019
Enrollment StartMar 23, 2020
Primary CompletionJan 4, 2023
Study CompletionFeb 23, 2023
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 6.5 years ago
Interventions
aldaferminbiological
aldafermin
Placeboother
Placebo for aldafermin